Pharnext SA
PAR:ALPHA
Pharnext SA
Total Liabilities
Pharnext SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Total Liabilities
€35.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€297.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€164.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
29%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€187.9m
|
CAGR 3-Years
69%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities
$57.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
16%
|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities
€168m
|
CAGR 3-Years
32%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Total Liabilities?
Total Liabilities
35.7m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Total Liabilities amounts to 35.7m EUR.
What is Pharnext SA's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-3%
Over the last year, the Total Liabilities growth was 1%. The average annual Total Liabilities growth rates for Pharnext SA have been 7% over the past three years , -3% over the past five years .
